DNMT3A and acute myeloid leukemia: The themes of references with the highest frequency of citations are divided into three parts: guidelines (diagnosis and management of 2017 ELN recommendations, and 2016 WHO classification revision from 2016 WHO); reviews of prognostic relevance of genomic classification and epigenetic landscapes (DNMT3A mutations) in AML; and targeted drugs for AML (midostaurin plus chemotherapy for FLT3 mutation, and enasidenib for relapsed or refractory AML).